Publication: A Study on the Diversity of Pharmacogenomic Variants Aff ecti ng Dapsone Hypersensiti vity: A Comparati ve Study Based on South Asian and Other World Populati ons
Type:
Article
Date
2024-12-04
Journal Title
Journal ISSN
Volume Title
Publisher
Faculty of Humanities and Sciences, SLIIT
Abstract
Recent data from Sri Lanka indicates an increase
in leprosy cases, emphasizing the necessity of
dapsone as a drug vital for managing it. Ironically,
dapsone eff ecti veness is accompanied by dapsone
hypersensiti vity syndrome (DHS) which varies
among populati ons. We postulate that this is due to
signifi cant diff erences between SNP frequencies in
HLA-B*13:01, CYP2C9*3, rs701829, rs17211071, and
rs201929247. As per our reading, no comparati ve
study has been done so far on DHS and related
genes between South Asian (SAS) and other world
populati ons. Therefore, this study compares the
allele frequencies of SNPs from PharmGKB and
dbSNP of world populati ons against SAS using chisquare
(χ²) tests. For HLA-B*13:01; it is reported
that Europeans, Africans, African others, and
African Americans have demonstrated signifi cant
diff erences, and Asians, EAS, Other Asians, and Lati n
Americans have shown no signifi cant diff erences.
For CYP2C9*3 and rs701829; Americans, Africans,
Amish, Ashkenazi Jews, East Asians (EAS), Finns, and
Non-Finnish Europeans (NFE) all have demonstrated
a signifi cant diff erence from SAS. For rs17211071,
Africans, Amish, Americans, East Asians, Finns, and
NFE demonstrated no signifi cant diff erence, and ASJ
showed a signifi cant diff erence. For rs201929247,
Africans and Finns had no signifi cant diff erences,
whereas Americans, Amish, ASJ, EAS, and NFE had.
Hence, compared with other populati ons, allele
frequencies of some studied SNPs were signifi cantly
diff erent in SAS, and these may likely account for
the variability of DHS occurrence among these
populati ons. Signifi cant allele frequency diff erences
between SAS and the rest of the world populati ons’
impact personalized medicine in leprosy treatment.
Clinical research needs to determine the opti mal
dapsone dose alterati ons, considering environmental
and other factors behind DHS.
Description
Keywords
Pharmacogenomics, Personalized Medicine, Leprosy, DHS, Dapsone
